Audion Announces Investment and Licensing Deal with Lilly
News Feb 11, 2014

Audion Therapeutics has announced that it has received a Series A investment from Eli Lilly and Company to enable the company to progress its programs targeting sensorineural hearing loss.
As part of the investment, the parties also entered into a licensing agreement that gives Audion the rights to certain Lilly compounds that can be developed to potentially treat hearing loss by hair cell regeneration.
Under the terms of the license, Lilly has an option to reacquire these rights upon successful clinical Proof of Concept. Financial terms were not disclosed. Following the investment, Mr. Shaun Hawkins, Vice President of Lilly New Ventures, has become a member of Audion’s Supervisory Board.
Rolf Jan Rutten, CEO of Audion commented: “This commitment by Lilly is an important next step in the development of our company. The investment validates our scientific approach and it underlines the potential of our hair cell regeneration program. It allows us to expand our infrastructure with a laboratory facility in Cambridge, Mass. and gives us access to a selection of Lilly’s potent, proprietary molecules that will push Audion’s lead program significantly forward”.
RELATED ARTICLES
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine Yields
NewsExtends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.
READ MORELonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in Texas
NewsFirst-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.
READ MOREIONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE Antibodies
NewsThe project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.
READ MOREComments | 0 ADD COMMENT
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREEAsia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
Login
You must be logged in to post a comment.